Ongoing Clinical Trials for Milk Allergy
There are currently 2 clinical trials investigating treatments for milk allergy, focusing on infants and children with gastroesophageal reflux disease related to cow’s milk allergy and severe IgE-mediated cow’s milk allergy. These studies are exploring the effectiveness of dietary interventions, medications to reduce stomach acid, and immunotherapy combined with allergy medications.
Clinical trial locations
- Denmark
- Spain
Study on Omeprazole and Cow’s Milk-Free Diet for Treating Gastroesophageal Reflux Disease in Infants Under 1 Year
This trial is taking place in Denmark and focuses on treating gastroesophageal reflux disease in infants who may also have a cow’s milk allergy. The study is testing whether a medication called Omeprazole or a cow’s milk-free diet can help reduce reflux symptoms in babies under one year of age.
Who can participate: Infants must be under 1 year old and diagnosed with gastroesophageal reflux disease, experiencing at least 3 reflux episodes daily. Additionally, they must show at least one troublesome symptom such as unexplained crying, discomfort, weight issues, feeding difficulties, pauses in breathing, or back-arching. The infant must be older than 1 month when treatment begins, and both male and female infants are eligible.
Who cannot participate: Infants older than 1 year are not eligible. Those who do not have gastroesophageal reflux disease or a cow’s milk allergy cannot join the study. The trial is designed for a specific vulnerable population, so infants outside this group are excluded.
Treatment being tested: The study is investigating two main approaches. The first is a cow’s milk-free diet, which removes all cow’s milk from the infant’s nutrition to see if this reduces reflux episodes. The second is Omeprazole, a proton pump inhibitor that decreases the amount of acid produced in the stomach. These treatments will be compared against a placebo to determine their effectiveness.
What the study involves: Parents will be asked to track their child’s reflux episodes daily using a mobile application throughout the four-week treatment period. They will also monitor and report any changes in symptoms such as crying, discomfort, or feeding difficulties. Healthcare providers will closely watch for any side effects and assess changes in the child’s weight and overall symptom improvement. For infants in the diet group, after four weeks of avoiding cow’s milk, an oral provocation test will be conducted to confirm whether a milk allergy is present.
Study on the Safety and Effectiveness of Low-Dose Oral Immunotherapy with Omalizumab for Children with Severe Cow’s Milk Allergy
This trial is being conducted in Spain and is designed for children with severe IgE-mediated cow’s milk allergy. The study aims to determine whether combining low-dose oral immunotherapy with a medication called Omalizumab can help children build tolerance to cow’s milk and reduce allergic reactions.
Who can participate: Children between 6 and 15 years old with a documented history of allergic reactions to cow’s milk can join the study. They must have experienced episodes of anaphylaxis from consuming cow’s milk or have been diagnosed with asthma. Blood tests must show high levels of IgE antibodies to cow’s milk and casein, and skin tests must be positive for these allergens. Participants must weigh more than 19 kilograms and be willing to receive injections, undergo oral challenge tests, and continue exposure to cow’s milk throughout the study. Both parents or legal guardians and the children themselves must provide written consent.
Who cannot participate: Children who do not have a severe IgE-mediated cow’s milk allergy are not eligible. Those outside the specified age range cannot participate. Anyone unwilling to follow the study procedures, those with other health conditions that might interfere with the study, and pregnant individuals or those planning to become pregnant during the study are excluded. Children currently participating in another clinical trial are also not eligible.
Treatment being tested: The study uses Omalizumab, a medication given by injection under the skin that works by blocking IgE antibodies responsible for triggering allergic reactions. This is combined with oral immunotherapy, where small, gradually increasing amounts of milk protein are given to the child under medical supervision. The goal is to help the child’s body become less sensitive to cow’s milk over time.
What the study involves: After initial assessments confirm eligibility, children will begin receiving Omalizumab injections according to a specific schedule. They will then start low-dose oral immunotherapy with cow’s milk protein. Throughout the study, which lasts up to 18 months, participants will be closely monitored for allergic reactions and side effects. Regular check-ups will assess how well they tolerate increasing amounts of milk protein. The study will conduct oral challenge tests in controlled environments to evaluate whether children can safely tolerate 300 milligrams of cow’s milk protein without severe symptoms. At the end of the trial, a final evaluation will determine the overall safety and effectiveness of this combined treatment approach.
Summary
The two ongoing clinical trials for milk allergy reflect different approaches based on age and severity of the condition. The Danish study focuses on very young infants under one year with reflux disease that may be related to cow’s milk allergy, testing both dietary changes and acid-reducing medication. The Spanish study targets older children aged 6 to 15 with severe allergic reactions, exploring whether immunotherapy combined with allergy medication can help build long-term tolerance.
These trials are geographically concentrated in Europe, with one study in Denmark and one in Spain. Both studies emphasize careful monitoring and safety, recognizing that milk allergy can cause significant discomfort and potentially dangerous reactions. The treatments being investigated range from simple dietary elimination to more complex approaches involving gradual exposure to allergens under medical supervision. While these trials offer hope for better management options, it is important to remember that they are still in the research phase, and their effectiveness is being evaluated.
